Bluebird Bio to Present 6 abstracts at ASH

 Six abstracts accepted for presentation –

– Interim data on LentiGlobin in beta-thalassemia show six of six evaluable non-β⁰/β⁰ patients are transfusion-independent as of July 31^st data cut-off; β⁰/β⁰ patients have achieved varying degrees of transfusion reduction as of data cut-off –

    – Median production of corrected HbA^T87Q globin: 5.2 g/dL among patients of all genotypes followed for at least six months in HGB-204 study, as of July 31^st data cut-off –

    – Patient with sickle cell disease from HGB-205 study producing 51.5% anti-sickling hemoglobin at nine months post-treatment –

– Company will discuss ASH abstract data in a conference call today at 8:30 a.m. ET–

http://finance.yahoo.com/news/bluebird-bio-present-lentiglobin-bb305-130000247.html